What is MyMD Pharmaceuticals Financial Strength?
MyMD Pharmaceuticals has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
MyMD Pharmaceuticals has no long-term debt (1).
As of today, MyMD Pharmaceuticals's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of MyMD Pharmaceuticals's Financial Strength
For the Biotechnology subindustry, MyMD Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MyMD Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MyMD Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where MyMD Pharmaceuticals's Financial Strength falls into.
MyMD Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
MyMD Pharmaceuticals's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-2.79 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
MyMD Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is
| MyMD Pharmaceuticals had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. MyMD Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
MyMD Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
MyMD Pharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.
Executives
| Paul Rivard |
officer: EVP of Operations, GC |
C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
| Joshua Silverman |
director |
IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
| Caroline C Williams |
10 percent owner |
324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
| Adam Kaplin |
officer: Chief Scientific Officer |
C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
| Jude Uzonwanne |
director |
C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
| Craig Eagle |
director |
POST OFFICE BOX 4590, NEW YORK NY 10163 |
| Chapman Christopher C Jr |
director, officer: President, Chief Med. Officer |
C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814 |
| Ian Rhodes |
officer: Interim CFO |
1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824 |
| Stuart M Benson |
officer: Chief Financial Officer |
EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118 |
| Hudson Bay Capital Management Lp |
10 percent owner |
28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
| Sander Gerber |
10 percent owner |
C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
| Robert C Schroeder |
director |
37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724 |
| Howard Yeaton |
officer: CEO, CFO |
79 LLOYD ROAD, HOHOKUS NJ 07423 |
| Tarbox Richard C Iii |
director |
AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
| Christopher C Schreiber |
director |
AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYMD has been successfully added to your